The transdermal delivery system, D'OXYVA®, has been used in hundreds of thousands of successful applications, many of them verified by some of the most advanced FDA-approved diagnostic methods.
Pasadena, California (PRWEB) October 12, 2015
Norbert Kiss, president and CEO of Circularity™ - Circularity Healthcare™ - a company specializing in non-invasive technologies for highly portable medical gas-powered transdermal delivery, reports that the completion of five successful landmark clinical studies demonstrate the efficacy of the company's delivery system in helping lower the risk of hypertension, high blood pressure, diabetes, cancer (e.g., multiple myeloma, lupus, skin, lung, brain), chronic diabetic and peripheral artery disease (PAD) related wounds; the system is also effective in improving quality of life, such as promoting significantly deeper sleep, reducing or eliminating chronic and acute pain, and boosting appetite, energy and mood. The studies were completed by Dr. Chester Ray, PhD, Penn State University; Dr. Lee C. Rogers, Valley Presbyterian Hospital; Dr. Harikrishna K. R. Nair, Hospital Kuala Lumpur; Janine Esler and Dr. Karen Indreland at Esler Arabian in Sacramento, Calif.
The transdermal delivery system, D'OXYVA®, has been used in hundreds of thousands of successful applications, many of them verified by some of the most advanced FDA-approved diagnostic methods. Successful tests with D'OXYVA® were completed on users with a wide variety of mild to extremely severe conditions, resulting in numerous positive outcomes.
D'OXYVA® has shown great promise in the wound care market, because the delivery system is non-invasive, painless, easy-to-use, with relatively affordable applications that make it highly competitive. Currently, leading advanced wound care technology is Negative Pressure Wound Therapy (NPWT), which is rarely considered adequate by wound care physicians. The company announced this month the launching of a multicenter wound healing clinical trial with internationally renowned doctors as principal investigators, setting the stage for its upcoming U.S. FDA clearance process. The clinical trial comes on the heels of successful wound healing pilot studies in which wound healing was recorded in severe late stage diabetic foot wounds, with all subjects reporting pain reduction, and marked improvement in their sleep, eating, and mood.
About Circularity Healthcare
Circularity Healthcare, LLC, headquartered in the U.S. is an emerging world leader in proprietary circulatory health and non-invasive delivery technologies, committed to helping improve lives by developing, manufacturing, and marketing consumer health and wellness products. Circularity specializes in groundbreaking non-invasive technologies for highly portable medical gas-powered transdermal delivery systems and is pursuing regulatory approvals worldwide for device usage as treatment of disease states related to cardiovascular blood flow.
Pennsylvania State University (Penn State) is a leader in higher education and carries out its mission of teaching, research, and service with pride and focus on the future. Penn State is a major, public, research-intensive university serving Pennsylvania and the global community. Founded in 1855, the university has a stated threefold mission of teaching, research, and public service. Its instructional mission includes undergraduate, graduate, professional and continuing education offered through resident instruction and online delivery.
Valley Presbyterian Hospital opened its doors to the community in 1958 as a small, neighborhood provider of personalized medical care. Today, we are one of the largest and most prestigious full-service acute care facilities in the San Fernando Valley. Our 350-bed hospital serves thousands of families each year, with access to a wide range of medical expertise and leading-edge technology across all elements of care. Among the region’s brightest and best, our nurses, therapists, technicians and more than 500 physicians represent virtually every specialty and most sub-specialties in the medical field, including cardiac care, orthopedics, maternal and child health, and oncology.
About Hospital Kuala Lumpur
Hospital Kuala Lumpur is now the largest hospital under the Ministry of Health of Malaysia and is considered to be one of the biggest in Asia. It is a government tertiary referral hospital, located on 150 acres of prime land with 83 wards and 2,300 beds. The Kuala Lumpur Hospital or commonly known as HKL (Hospital Kuala Lumpur) has 53 different departments and units. These include the administration & finance department, the pharmaceutical department, training and research, 28 clinical departments and 12 clinical support services.
About Esler Arabians
Janine Esler is one of the most successful endurance trainers in the country. She trains all breeds of horses in many disciplines but specializes in Arabian horses and endurance training for the horse and rider. Janine also specializes in "problem" horses and solving those problems for the life of the horse. Janine lives in Granite Bay, California, where she also breeds champion Arabian horses including her Khemosabi son, Khemistreetu. She has 6 Tevis Cup buckles and has successfully completed scores of horses on multi-day 250 and 50 mile rides. She stresses safety for horse and rider as well as enjoyment and longevity. Janine has hosted many training clinics and has been a featured speaker at the 2001 AERC convention in Reno. She has authored the monthly "Ask a Trainer" column in the AERC News as well as the Tevis Cup Website.
For More Information
Please visit http://www.circularityhealthcare.com or http://www.doxyva.com and send your general inquiries via the Contact Us page, or for specific inquiries contact Circularity Public Relations at pr(at)circularityhealthcare(dot)com or by phone toll free at 1-855-5DOXYVA or at 1-626-817-6685 or 1-626-244-8090.
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.
For the original version on PRWeb visit: http://www.prweb.com/releases/circularitydoxyva/clinicalevidence/prweb13008154.htm